Tuberculosis Clinical Trial
— MAT K43Official title:
Real-time Tuberculosis Medication Adherence Intervention in Rural Southwestern Uganda
With an estimated 60,000 people diagnosed with TB (Tuberculosis) annually, Uganda holds the
16th position of the 22 countries with highest cases of TB in the world. The Uganda national
target of utilizing the DOTS (Direct Observed Treatment Short Course) to successfully treat
85% of patients diagnosed with TB has not been met. Currently, the country only detects 49.6%
TB case detection, of which it successfully treats 73%. The DOTS strategy has suffered many
socioeconomic challenges, which have resulted into its abandonment by many of the Ugandan
hospitals. Poor TB medication adherence greatly attribute to the many cases of TB in Uganda.
Causes of non-adherence to TB medication include lack of patient follow-up, patients' lack of
transport to go to the clinics to pick up drugs, patients' forgetfulness. There is evidence
that real time adherence monitoring linked with SMS reminders and social support
notifications can address barriers to sustained ART (antiretroviral therapy) adherence. Such
novel interventions addressing TB medication adherence challenges in low resource settings to
date are limited. The prevailing SMS-based studies for TB medication adherence report mixed
results, do not strategically link interventions with missed doses, and have largely been
implemented in developed countries. To date, little is known about the use of real-time
adherence monitoring technologies for TB medication adherence in resource-limited settings.
The goal of this research is to investigate the use of real time adherence monitoring
technology linked with SMS reminders and notifications for TB medication adherence in rural
southwestern Uganda.
The investigator will develop and quantitatively test a real-time adherence monitoring
intervention with 60 individuals initiating TB treatment, and 40 social supporters. The
investigator will randomize participants (1:1:1) to the following arms: 1) Fixed and linked
SMS reminders, 2) SMS notifications to social supporters, and 3) no SMS (control). All
participants will have adherence monitored in real-time for 6 months.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | July 2021 |
Est. primary completion date | June 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Inclusion criteria for Wisepill participants: - Newly diagnosed with TB per the clinic records - Starting TB treatment now or within the next two weeks - Age 18 years and older - Live in the Mbarara District (20 km from MRRH) - Own a cell phone for personal use and have reliable cellular phone reception at home on networks (MTN or Airtel) supported by the technology used in this study - Know how to use SMS - Willing and able to give consent - Willing and able to name one or two social supporters who are able to use SMS and have cellular phones using network provider (MTN or Airtel) supported by the technology used in this study. Exclusion Criteria for Wisepill Participants: - Unable to use SMS (The investigators will train and test this skill at recruitment) - Unwilling to receive SMS reminder - Severe mental condition limiting the ability to provide consent - Cellular phone reception is not reliable Inclusion Criteria for Social Supporters - Know a Wisepill participant and be aware s/he has TB - Have provided help to that Wisepill participant at least once, i.e, - Helping him/her get to clinic by loaning or giving money, driving the patient , or taking care of his/her job or children while he/she is away - Helping the patient take medicines through encouragement or reminders - Motivating the patient to take medicines, including addressing cognitive and behavioral barriers such as depression and alcohol use - Age 18 years or older - Live in Mbarara District (within 20 KM from MRRH) - Willing and able to provide consent. Exclusion: - Unable to use SMS (Investigators will train and test this skill at recruitment) - Unwilling to receive SMS reminder - Severe mental condition limiting the ability to provide consent - Cellular phone reception is not reliable |
Country | Name | City | State |
---|---|---|---|
Uganda | Mbarara Regional Referral Hospital | Mbarara |
Lead Sponsor | Collaborator |
---|---|
Mbarara University of Science and Technology | Massachusetts General Hospital, National Institutes of Health (NIH) |
Uganda,
Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G, Bai L, Li J, Li X, Chen H, Liu M, Chen R, Chi J, Lu J, Huan S, Cheng S, Wang L, Jiang S, Chin DP, Fielding KL. Effectiveness of Electronic Reminders to Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised Trial. PLoS Med. 2015 Sep 15;12(9):e1001876. doi: 10.1371/journal.pmed.1001876. eCollection 2015 Sep. — View Citation
Musiimenta A. A Controlled Pre-Post Evaluation of a Computer-based HIV/AIDS Education on Students' Sexual Behaviors, Knowledge and Attitudes. Online J Public Health Inform. 2012;4(1). pii: ojphi.v4i1.4017. doi: 10.5210/ojphi.v4i1.4017. Epub 2012 May 17. — View Citation
Musiimenta A. Contextual Mediators influencing the Effectiveness of Behavioural Change Interventions: A Case of HIV/AIDS Prevention Behaviours. Online J Public Health Inform. 2012;4(2). pii: ojphi.v4i2.3988. doi: 10.5210/ojphi.v4i2.3988. Epub 2012 Sep 14. — View Citation
Musiimenta A. Social and Institutional issues in the Adoption of School-based Technology-aided Sexual Health Education Program. Online J Public Health Inform. 2013 Jul 1;5(2):213. doi: 10.5210/ojphi.v5i2.4654. Print 2013. — View Citation
Nglazi MD, Bekker LG, Wood R, Hussey GD, Wiysonge CS. Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review. BMC Infect Dis. 2013 Dec 2;13:566. doi: 10.1186/1471-2334-13-566. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent adherence | SPSS (statistical package for social scientists) will be used, to determine the mean (standard deviation), median (interquartile range), number of late doses, number of missed doses, and number of hour gaps in adherence as determined by Wisepill for each stage of the intervention, as well as for the control group. The Investigator will compare adherence during each type of SMS reminder with adherence during the matched time period for the control group using T-tests (or Mann-Whitney U tests, depending on the normality of the data) for continuous data and chi-squared tests for categorical data. | 12 Weeks | |
Secondary | Treatment success rate. | The Investigator will determine the mechanisms of effect and context of an integrated adherence monitoring, SMS reminders and social support interventions. | 24 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |